TESARO Announces Achievement of ZEJULA Prostate Cancer Development Milestones by Janssen
TESARO (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the achievement of development milestones that trigger an $18 million payment from Janssen Biotech. The milestones are related to Janssen’s ongoing GALAHAD trial, which is assessing niraparib monotherapy for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair anomalies. As quoted in the press … Continued
TESARO (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the achievement of development milestones that trigger an $18 million payment from Janssen Biotech. The milestones are related to Janssen’s ongoing GALAHAD trial, which is assessing niraparib monotherapy for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair anomalies.
As quoted in the press release:
In addition, data from the Phase 1b BEDIVERE trial were recently presented at the European Society of Clinical Oncology (ESMO) and demonstrated the safety and tolerability of combining niraparib with abiraterone acetate + prednisone (AA-P) in men with mCRPC. Data from the BEDIVERE trial will be used to inform the dosing regimen in a future Phase 3 trial that will assess the clinical benefit of niraparib in combination with AA-P in mCRPC patients.
TESARO entered into a global prostate collaboration and license agreement with Janssen in 2016, through which Janssen received rights to develop and commercialize niraparib for patients with prostate cancer worldwide, except Japan. Under the terms of the agreement, TESARO is eligible to receive development, regulatory and commercial milestones, in addition to royalty payments.
Click here to read the full press release.
